Syndax Pharmaceuticals, Inc.
SNDXNASDAQHealthcare● Active
$16.96
$-0.38(-2.19%)
Market Cap$1.5B
P/E Ratio—
52W High$25.59
52W Low$8.585
Syndax Pharmaceuticals, Inc. (SNDX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SNDX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.17B | $0.02B | $0.00B | $0.00B | $0.14B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.17B | $0.02B | $0.00B | $0.00B | $0.14B |
| Gross Margin %(computed) | 95.96% | 96.51% | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.26B | $0.24B | $0.16B | $0.12B | $0.09B |
| G&A Expenses | $0.18B | $0.12B | $0.07B | $0.03B | $0.03B |
| Total Operating Expenses | $0.44B | $0.36B | $0.23B | $0.15B | $0.11B |
| Operating Income | ($0.27B) | ($0.34B) | ($0.23B) | ($0.15B) | $0.03B |
| Operating Margin %(computed) | -158.45% | — | — | — | 18.77% |
| Interest Income | $0.02B | $0.03B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.03B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.29B) | ($0.32B) | ($0.21B) | ($0.15B) | $0.02B |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.29B) | ($0.32B) | ($0.21B) | ($0.15B) | $0.02B |
| Net Margin %(computed) | -165.60% | — | — | — | 17.84% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.29 | $-3.73 | $-2.98 | $-2.46 | $0.48 |
| Wtd Avg Shares | 0.09B | 0.09B | 0.07B | 0.06B | 0.05B |
| EBITDA | ($0.25B) | ($0.31B) | ($0.21B) | ($0.15B) | $0.03B |
| EBITDA Margin %(computed) | -146.00% | — | — | — | 19.23% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Syndax Pharmaceuticals, Inc. data
About Syndax Pharmaceuticals, Inc. (SNDX) Income Statement
Syndax Pharmaceuticals, Inc. (SNDX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SNDX reported revenue of $0.17B, gross profit of $0.17B (gross margin 95.96%), and net income of ($0.29B) — a net profit margin of -165.60%.
Frequently asked questions
SNDX · 4 questionsSyndax Pharmaceuticals, Inc. (SNDX) reported revenue of $0.17B for 2025, up 627.8% year-over-year.
SNDX revenueSNDX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08